Disclosures for "A Case of Reversible Cerebral Vasoconstriction Syndrome (RCVS) After Axitinib and Pembrolizumab Therapy"
-
Dr. Bawaneh has nothing to disclose.
-
Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam.
-
Dr. Prajapati has nothing to disclose.